FDA Approves First New Alzheimer’s Drug In Nearly 20-Years

Biogen Image.

WASHINGTON – The Food and Drug Administration have approved a new, experimental drug to treat Alzheimer’s Disease.

Biogen’s medication is called Aducanumab, and it’s for mild cognitive impairment associated with the early stages of the brain wasting disease.








The decision comes seven months after all ten members of the Peripheral and Central Nervous System drugs advisory committee voted there is not enough evidence to show the drug is effective.

Some non-profits also didn’t think the medication should be approved, though, the Alzheimer’s association supported it.





It will take several months for the drug to become available for most patients. Some stakeholders have also voiced concern the drug may be too expensive.

It’s not known exactly how much it would cost patients. It’s been nearly 20 years since the agency has approved a new medication to treat the disease.















 

Make it easy to keep up to date with more stories like this. Download the WNY News Now mobile app on the Apple App Store and Google Play Store.

 

Have a news tip? Email newsdesk@WNYNewsNow.com, send us a message on Facebook, or Twitter.

WNY News Now encourages an open exchange of opinions and ideas on our stories, however, we ask everyone to follow our comment policy.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.